Profile data is unavailable for this security.
About the company
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
- Revenue in USD (TTM)3.32m
- Net income in USD-12.21m
- Incorporated2018
- Employees8.00
- LocationMarker Therapeutics Inc4551 KENNEDY COMMERCE DR.HOUSTON 77032United StatesUSA
- Phone+1 (713) 400-6400
- Fax+1 (302) 655-5049
- Websitehttps://markertherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomx Inc | 0.00 | -37.14m | 29.46m | 58.00 | -- | -- | -- | -- | -0.6234 | -0.6234 | 0.00 | 0.3813 | 0.00 | -- | -- | 0.00 | -60.38 | -- | -72.74 | -- | -- | -- | -- | -- | -- | -2.25 | 0.00 | -- | -- | -- | 7.59 | -- | -- | -- |
| Palatin Technologies, Inc. | 5.90m | -32.20m | 29.53m | 34.00 | -- | 18.70 | -- | 5.00 | -2.39 | -2.39 | 0.4275 | 0.0979 | 0.3189 | 0.6402 | 6.95 | 173,588.80 | -173.98 | -26.11 | -387.23 | -30.68 | 96.58 | -- | -545.58 | -126.20 | 1.20 | -- | 0.0443 | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
| Unicycive Therapeutics Inc | 0.00 | -37.82m | 30.30m | 14.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | 0.5779 | 0.00 | -- | -- | 0.00 | -92.81 | -218.20 | -221.58 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.57m | 30.60m | 0.00 | -- | -- | -- | -- | -0.0929 | -0.0929 | 0.00 | -0.0055 | 0.00 | -- | -- | -- | -624.25 | -- | -- | -- | -- | -- | -- | -- | -- | -173.44 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -15.53m | 30.79m | 29.00 | -- | -- | -- | -- | -0.3227 | -0.3227 | 0.00 | -0.0811 | 0.00 | -- | -- | 0.00 | -276.90 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| Promis Neurosciences Inc | 0.00 | -11.89m | 31.13m | 6.00 | -- | 403.74 | -- | -- | -0.8292 | -0.8292 | 0.00 | 0.0041 | 0.00 | -- | -- | 0.00 | -298.08 | -144.28 | -- | -262.23 | -- | -- | -- | -2,271,047.00 | -- | -- | 0.00 | -- | -- | -- | 26.85 | -- | -- | -- |
| IGC Pharma Inc | 1.22m | -14.15m | 31.58m | 61.00 | -- | 3.34 | -- | 25.97 | -0.2479 | -0.2479 | 0.0217 | 0.142 | 0.0776 | 0.2084 | 7.09 | 19,934.43 | -90.30 | -33.35 | -100.90 | -35.84 | 51.40 | 8.74 | -1,163.24 | -410.26 | 0.8564 | -- | 0.0153 | -- | 129.47 | -16.11 | 23.38 | -- | 25.28 | -- |
| Rapid Micro Biosystems Inc | 23.10m | -51.90m | 32.15m | 193.00 | -- | 0.3029 | -- | 1.39 | -1.20 | -1.20 | 0.5355 | 2.48 | 0.1535 | 1.37 | 4.34 | 119,663.20 | -34.49 | -- | -38.20 | -- | -22.59 | -- | -224.73 | -- | 5.62 | -- | 0.0028 | -- | 31.44 | -- | 13.71 | -- | -- | -- |
| Goldenwell Biotech Inc | 1.08k | -114.27k | 32.42m | -- | -- | 603.21 | -- | 30,020.83 | -0.0012 | -0.0012 | 0.00001 | 0.0005 | 0.0052 | 0.0035 | -- | -- | -54.62 | -- | -54.97 | -- | 43.52 | -- | -10,580.56 | -- | 20.18 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
| Marker Therapeutics Inc | 3.32m | -12.21m | 32.46m | 8.00 | -- | 2.75 | -- | 9.78 | -1.38 | -0.636 | 0.3751 | 1.32 | 0.158 | -- | 1.69 | 415,107.50 | -58.12 | -53.74 | -70.75 | -62.25 | -- | -- | -367.79 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| ImmuCell Corp | 21.28m | -3.90m | 33.59m | 74.00 | -- | 1.35 | -- | 1.58 | -0.5030 | -0.5030 | 2.75 | 3.18 | 0.494 | 2.29 | 9.03 | 269,401.50 | -9.05 | -5.16 | -9.97 | -5.53 | 27.55 | 40.04 | -18.31 | -12.64 | 1.00 | -8.14 | 0.3204 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| Nuo Therapeutics Inc | 782.01k | -3.02m | 33.83m | -- | -- | 99.51 | -- | 43.26 | -0.071 | -0.071 | 0.0183 | 0.0075 | 0.4516 | 0.7856 | 4.30 | -- | -174.64 | -116.16 | -294.62 | -354.84 | 78.74 | 70.02 | -386.76 | -854.53 | 1.01 | -1,418.93 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -2.16m | 34.44m | -- | -- | 3.31 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
| Vyne Therapeutics Inc | 423.00k | -28.50m | 35.01m | 10.00 | -- | 0.4134 | -- | 82.77 | -5.26 | -5.42 | 0.021 | 5.83 | 0.0067 | -- | -- | 42,300.00 | -44.91 | -108.41 | -50.67 | -138.57 | -- | -- | -6,738.06 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| OncoCyte Corp | 1.38m | -40.66m | 35.42m | 43.00 | -- | 1.89 | -- | 25.63 | -4.94 | -4.94 | 0.1682 | 2.05 | 0.018 | -- | 1.34 | 32,139.54 | -51.95 | -35.11 | -58.73 | -39.71 | 22.07 | -- | -2,890.23 | -2,373.36 | -- | -157.69 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
Data as of Jun 07 2024. Currency figures normalised to Marker Therapeutics Inc's reporting currency: US Dollar USD
9.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Aisling Capital Management LPas of 31 Mar 2024 | 314.29k | 3.53% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 230.72k | 2.59% |
| AR Asset Management, Inc.as of 31 Mar 2024 | 70.70k | 0.79% |
| Geode Capital Management LLCas of 31 Mar 2024 | 67.05k | 0.75% |
| Wedbush Securities, Inc. (Investment Management)as of 31 Mar 2024 | 45.50k | 0.51% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 37.25k | 0.42% |
| NFS Netfonds Financial Service GmbHas of 30 Sep 2023 | 25.44k | 0.29% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 22.85k | 0.26% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 20.28k | 0.23% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 19.75k | 0.22% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
